denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: The Expanding Landscape of Treatment for ITP
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Autoimmune disorders, Combination therapy, Drug development, Clinical Research, Platelet disorders, Education, Patient-reported outcomes, Diseases, Immune Disorders, Real-world evidence, Treatment Considerations, Biological therapies, Immunotherapy, Infusion, Adverse Events, Monoclonal Antibody Therapy
Session: The Expanding Landscape of Treatment for ITP
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Autoimmune disorders, Combination therapy, Drug development, Clinical Research, Platelet disorders, Education, Patient-reported outcomes, Diseases, Immune Disorders, Real-world evidence, Treatment Considerations, Biological therapies, Immunotherapy, Infusion, Adverse Events, Monoclonal Antibody Therapy
Saturday, December 7, 2024, 9:30 AM-10:45 AM
Disclosures: Lambert: Octapharma, Dova, Principia, Rigel, Argenx, PDSA, 22qSociety and CdLS Foundation: Membership on an entity's Board of Directors or advisory committees; Novartis Dova, Principia, Argenx, Rigel, Sobi, Sanofi and Janssen: Consultancy; FWGBD, PDSA, NIH, Sysmex, Novartis, Principia, Argenx, Dova, Octapharma and Sanofi: Research Funding.
OffLabel Disclosure: All the discussed therapies will be off label as they have not yet been approved by FDA for use in ITP.
<< Previous Presentation
|
Next Presentation